Nahdi NA, Lam MCW, Yoshida EM

Language: English
References: 18
Page: 115-118
PDF size: 40.28 Kb.

Text Extraction

Non-alcoholic fatty liver disease and the metabolic syndrome in an urbran hospital serving an African community

Onyekwere C.A, et al. The term nonalcoholic fatty liver disease (NAFLD) is used to describe a spectrum of histologic findings ranging from simple steatosis to nonalcoholic steatohepatitis with progressive fibrosis. Diabetes, obesity and metabolic syndrome are risk factors for NAFLD, and it is present in 50% of diabetics and 76% of obese individuals. In a large population based cohort study, NAFLD was detected in one third of the American adults. In this issue, Onyekwere, et al., present data on the prevalence of NAFLD in Nigeria, and compare the prevalence of the disease in the diabetic and non-diabetic subjects.

REFERENCES

1. Charlton M. Nonalcoholic Fatty Liver Disease: A Review of Current Understanding and Future Impact. JAMA 2004; 2: 1048-58.

2. Adams LA, Angulo P, Lindor K. Nonalcoholic Fatty Liver Disease. CMAJ 2005; 172(7): 899-905.

3. Browning J, Szczepaniak L, Dobbins R, et al. Prevalence of Hepatic steatosis in an urban population in the United States: the impact of ethnicity. Hepatology 2004; 40: 1387-95.

4. Giday SA, Ashiny Z, Naab T, et al. Frequency of Nonalcoholic fatty liver and degree of hepatic steatosis in African-American Patients. J Natl Med Assoc 2006; 98: 1613-15.

5. Caldwell SH, Harris D.M, Patrie JT, et al. Is NASH underdiagnosed among African American? Am J Gastroenterol 2002: 97(6): 1496-500.

6. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990: 37: 663-76.

7. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004: 24: 198-211.

8. 8 Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990: 54: 12-7.

9. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009: 113: 2386-93.

10. Makar GA, Weiner MG, Kimmel SE, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf 2008: 17: 43-51.

11. Olivera-Martinez AM, Gallegos-Orezco JF. Recurrent Viral Liver Disease (Hepatitis B and C) After Liver Transplantation. Archives of Medical Research 2007; 38: 691-701.

12. Lucey MR, Graham DM, Martin P, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390.

13. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 989; 321: 1092.

14. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. NEJM 1993; 329: 1842-7.

15. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-5.

16. Seehofer D, Berg T. Prevention of Hepatitis B Recurrence after Liver Transplantation. Transplantation 2005; 80: S120- S124.

17. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-9.

18. Katz LH, Paul M, Guy D.G, et al. Prevention of recurrent HBV infectionafter liver transplantation: Hepatitis B immunoglobulin, antiviral drugs or both? Transpl Infec Dise 2010; 12: 292-308.